Geng Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Geng Tian has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Chao Xie
Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University , Shanghai 200433
1 shared publication - Cheng-Da Yuan
Department of Dermatology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou 310007, China
1 shared publication - Ching-Lung Cheung
Department of Pharmacology and Pharmacy, the University of Hong Kong, Hong Kong, China
1 shared publication - Chun-Fu Yu
Department of Orthopedic Surgery, Shangrao Municipal Hospital, Shangrao 334000, China
1 shared publication - David Karasik
The Musculoskeletal Genetics Laboratory, The Azrieli Faculty of Medicine, Bar-Ilan University
1 shared publication - Daxi Sun
School of Pharmacy Binzhou Medical University Yantai China
1 shared publication
Latest Publications
- Open Access
- 28 October 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 23 (5)
Genome-wide Association Studies of over 30,000 Samples with Bone Mineral Density at Multiple Skeletal Sites and Its Clinical Relevance
The ultimate goal of a genome-wide association study (GWAS) is to translate its discoveries into clinical practice. To explore the clinical use of GWAS findings in the bone field, we conducted a GWAS of dual-energy X-ray absorptiometry (DXA)-derived bone mineral density (BMD) traits at 11 skeletal sites, within over 30,000 European individuals from the UK Biobank. A total of 91 unique and independent loci were identified for 11 DXA-derived BMD traits and fractures, including 5 novel loci (harboring the genes ABCA1, CHSY1, CYP24A1, SWAP70, and PAX1) for 6 BMD traits. These loci exhibited evidence of association in both males and females, which could serve as independent replication. We demonstrated that each polygenic risk score (PRS) was independently associated with fracture risk. Although incorporating multiple PRSs (i.e., metaPRS) with clinical risk factors from the Fracture Risk Assessment Tool (FRAX) yielded the highest predictive performance, the improvement was modest in fracture prediction. Additionally, we uncovered genetic correlation and shared polygenicity between head BMD and intracranial aneurysm (IA). Finally, by integrating gene expression and GWAS datasets, we prioritized genes (e.g., ESR1 and SREBF1) encoding druggable human proteins along with their respective inhibitors/antagonists. In conclusion, this comprehensive investigation reveals a new genetic basis for BMD and its clinical relevance to fracture prediction. More importantly, it suggests that head BMD is genetically correlated with IA. The prioritization of genetically supported targets implies the potential repurposing of drugs [e.g., omega-3 polyunsaturated fatty acid (PUFA) supplements] for the prevention of osteoporosis.
- 28 October 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 23 (5)
Open AccessGenome-wide Association Studies of over 30,000 Samples with Bone Mineral Density at Multiple Skeletal Sites and Its Clinical Relevance
The ultimate goal of a genome-wide association study (GWAS) is to translate its discoveries into clinical practice. To explore the clinical use of GWAS findings in the bone field, we conducted a GWAS of dual-energy X-ray absorptiometry (DXA)-derived bone mineral density (BMD) traits at 11 skeletal sites, within over 30,000 European individuals from the UK Biobank. A total of 91 unique and independent loci were identified for 11 DXA-derived BMD traits and fractures, including 5 novel loci (harboring the genes ABCA1, CHSY1, CYP24A1, SWAP70, and PAX1) for 6 BMD traits. These loci exhibited evidence of association in both males and females, which could serve as independent replication. We demonstrated that each polygenic risk score (PRS) was independently associated with fracture risk. Although incorporating multiple PRSs (i.e., metaPRS) with clinical risk factors from the Fracture Risk Assessment Tool (FRAX) yielded the highest predictive performance, the improvement was modest in fracture prediction. Additionally, we uncovered genetic correlation and shared polygenicity between head BMD and intracranial aneurysm (IA). Finally, by integrating gene expression and GWAS datasets, we prioritized genes (e.g., ESR1 and SREBF1) encoding druggable human proteins along with their respective inhibitors/antagonists. In conclusion, this comprehensive investigation reveals a new genetic basis for BMD and its clinical relevance to fracture prediction. More importantly, it suggests that head BMD is genetically correlated with IA. The prioritization of genetically supported targets implies the potential repurposing of drugs [e.g., omega-3 polyunsaturated fatty acid (PUFA) supplements] for the prevention of osteoporosis.
- 31 August 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (17) , e70019
VEGF ‐B prevents chronic hyperglycemia‐induced retinal vascular leakage by regulating the CDC42 ‐ ZO1 / VE ‐cadherin pathway
Non‐proliferative diabetic retinopathy (NPDR) is the early stage of diabetic retinopathy (DR) and is a chronic oxidative stress‐related ocular disease. Few treatments are approved for early DR. This study aimed to investigate the pathogenic mechanisms underlying the retinal micro‐vasculopathy induced by diabetes and to explore an early potential for treating early DR in a mouse model. The mouse model of type 1 diabetes was established by intraperitoneal injection of streptozotocin (STZ, 180 mg/kg), which was used as the early DR model. The body weight and blood glucose mice were measured regularly; The retinal vascular leakage in the early DR mice was determined by whole‐mount staining; Label‐free quantitative proteomic analysis and bioinformatics were used to explore the target proteins and signaling pathways associated with the retinal tissues of early DR mice; To detect the effects of target protein on endothelial cell proliferation, migration, and tube formation, knockdown and overexpression of VEGF‐B were performed in human retinal vascular endothelial cells (HRECs); Western blotting was used to detect the expression of target proteins in vitro and in vivo; Meanwhile, the therapeutic effect of VEGF‐B on vascular leakage has also been evaluated in vitro and in vivo. The protein expressions of vascular endothelial growth factor (VEGF)‐B and the Rho GTPases family member CDC42 were reduced in the retinal tissues of early DR. VEGF‐B upregulated the expression of CDC42/ZO1/VE‐cadherin and prevented hyperglycemia‐induced vascular leakage in HRECs. Standard intravitreal VEGF‐B injections improved the retinal vascular leakage and neurovascular response in early DR mice. Our findings demonstrated, for the first time, that in diabetes, the retinal vessels are damaged due to decreased VEGF‐B expression through downregulation of CDC42/ZO1/VE‐cadherin expression. Therefore, VEGF‐B could be used as a novel therapy for early DR.
- 31 August 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (17) , e70019
VEGF ‐B prevents chronic hyperglycemia‐induced retinal vascular leakage by regulating the CDC42 ‐ ZO1 / VE ‐cadherin pathway
Non‐proliferative diabetic retinopathy (NPDR) is the early stage of diabetic retinopathy (DR) and is a chronic oxidative stress‐related ocular disease. Few treatments are approved for early DR. This study aimed to investigate the pathogenic mechanisms underlying the retinal micro‐vasculopathy induced by diabetes and to explore an early potential for treating early DR in a mouse model. The mouse model of type 1 diabetes was established by intraperitoneal injection of streptozotocin (STZ, 180 mg/kg), which was used as the early DR model. The body weight and blood glucose mice were measured regularly; The retinal vascular leakage in the early DR mice was determined by whole‐mount staining; Label‐free quantitative proteomic analysis and bioinformatics were used to explore the target proteins and signaling pathways associated with the retinal tissues of early DR mice; To detect the effects of target protein on endothelial cell proliferation, migration, and tube formation, knockdown and overexpression of VEGF‐B were performed in human retinal vascular endothelial cells (HRECs); Western blotting was used to detect the expression of target proteins in vitro and in vivo; Meanwhile, the therapeutic effect of VEGF‐B on vascular leakage has also been evaluated in vitro and in vivo. The protein expressions of vascular endothelial growth factor (VEGF)‐B and the Rho GTPases family member CDC42 were reduced in the retinal tissues of early DR. VEGF‐B upregulated the expression of CDC42/ZO1/VE‐cadherin and prevented hyperglycemia‐induced vascular leakage in HRECs. Standard intravitreal VEGF‐B injections improved the retinal vascular leakage and neurovascular response in early DR mice. Our findings demonstrated, for the first time, that in diabetes, the retinal vessels are damaged due to decreased VEGF‐B expression through downregulation of CDC42/ZO1/VE‐cadherin expression. Therefore, VEGF‐B could be used as a novel therapy for early DR.
- 1 July 2019
- Published by American Association for Cancer Research (AACR)
- Vol. 79 (13 Supplem) , 5102
Abstract 5102: Deep learning method for the classification of CNV based on the next generation target sequencing
Background: Copy number variations (CNVs) are of great importance to many cancers. Recently, the next-generation sequencing has made detecting CNV by sequencing possible. Traditional CNV determination methods involve expensive experiments, which is costly. Recently, several algorithms were proposed the detection of CNV, but none of them could utilize only the coverage information at a specific gene to make the determination of CNV at the gene. Methods: We collected 1132 samples with 51 mesenchymal-epithelial transition factor (MET) CNV samples and 1081 samples with no CNVs. We split the exons of MET to multiple 50-bp windows with the stride of 40-bp. At each window the supporting reads were counted, and reads numbers at each exons were piled up, generating a matrix. The training set containing 38 CNV-positive matrices and 38 CNV-negative matrices were extracted from all the matrices, leaving the others as the test set. The deep learning network, convolutional neural network (CNN) were applied to distinguish between the CNV-positive matrices and the CNV-negative matrices. For comparison, logistic regression model was also applied for the classification task. Results: The training set were split into 5 pieces containing 15 samples each and 5-fold cross validation were run for the CNN or the logistic regression model. After running 10 5-fold cross validation, we got an accuracy of 85.73 ± 9.24% for CNN and the average accuracy of 87.07 ± 8.99% for the logistic regression model. We chose 3 best models in both CNN and logistic regression models for the determination of the test set. The CNN models gained the accuracy of 71.84 ± 2.19% while the logistic regression models gained the accuracy of 69.70 ± 2.56%. Furthermore, the Area Under Curve (AUC) of the CNN models were 0.6335 ± 0.0124, higher than that of the logistic regression models which was 0.5666 ± 0.0115. Conclusions: We proposed a method to determine the samples with CNV by using the convolutional neural network with only the coverage information within the specific region. It provides the possibility of CNV detection for cancer patients using only the next generation sequencing data. Citation Format: Jidong Lang, Geng Tian. Deep learning method for the classification of CNV based on the next generation target sequencing [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5102.
- 1 July 2019
- Published by American Association for Cancer Research (AACR)
- Vol. 79 (13 Supplem) , 5102
Abstract 5102: Deep learning method for the classification of CNV based on the next generation target sequencing
Background: Copy number variations (CNVs) are of great importance to many cancers. Recently, the next-generation sequencing has made detecting CNV by sequencing possible. Traditional CNV determination methods involve expensive experiments, which is costly. Recently, several algorithms were proposed the detection of CNV, but none of them could utilize only the coverage information at a specific gene to make the determination of CNV at the gene. Methods: We collected 1132 samples with 51 mesenchymal-epithelial transition factor (MET) CNV samples and 1081 samples with no CNVs. We split the exons of MET to multiple 50-bp windows with the stride of 40-bp. At each window the supporting reads were counted, and reads numbers at each exons were piled up, generating a matrix. The training set containing 38 CNV-positive matrices and 38 CNV-negative matrices were extracted from all the matrices, leaving the others as the test set. The deep learning network, convolutional neural network (CNN) were applied to distinguish between the CNV-positive matrices and the CNV-negative matrices. For comparison, logistic regression model was also applied for the classification task. Results: The training set were split into 5 pieces containing 15 samples each and 5-fold cross validation were run for the CNN or the logistic regression model. After running 10 5-fold cross validation, we got an accuracy of 85.73 ± 9.24% for CNN and the average accuracy of 87.07 ± 8.99% for the logistic regression model. We chose 3 best models in both CNN and logistic regression models for the determination of the test set. The CNN models gained the accuracy of 71.84 ± 2.19% while the logistic regression models gained the accuracy of 69.70 ± 2.56%. Furthermore, the Area Under Curve (AUC) of the CNN models were 0.6335 ± 0.0124, higher than that of the logistic regression models which was 0.5666 ± 0.0115. Conclusions: We proposed a method to determine the samples with CNV by using the convolutional neural network with only the coverage information within the specific region. It provides the possibility of CNV detection for cancer patients using only the next generation sequencing data. Citation Format: Jidong Lang, Geng Tian. Deep learning method for the classification of CNV based on the next generation target sequencing [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5102.